Investigating the Roles of Pregnane X Receptor in Human Breast Cancers

This review synthesizes current knowledge about the Pregnane X Receptor (PXR, NR1I2) and its roles in human breast cancer growth and progression. PXR is a ligand-activated nuclear receptor notable for a broad activation profile responsive to many endobiotic and xenobiotic ligands. While traditionally studied for its regulatory roles in liver and gastrointestinal detoxification pathways, PXR is also biologically active in mammary tissue, where emerging evidence links it to multiple processes relevant to tumorigenesis. The authors highlight that PXR regulates expression of genes encoding key drug-metabolizing cytochrome P450 enzymes and enzymes involved in oxidative stress responses, steroid metabolism, and bile acid metabolism. In breast cancer, elevated levels of PXR expression have been observed in cancerous tissue, suggesting an interface between mechanisms that protect cells from xenobiotic insults and the dysregulated proliferation characteristic of malignancy.

Functionally, PXR exerts a positive influence on the cell cycle, which can predispose tumor cells to unchecked proliferation. Beyond promoting proliferation, PXR activation affects apoptotic pathways and has been implicated in acquired resistance to chemotherapeutic agents, underscoring PXR’s potential contribution to treatment failure and disease progression. The review also addresses PXR’s role in modulating inflammatory mediators; PXR-mediated repression of inflammation may interact with carcinogenic processes in the breast microenvironment. Genetic polymorphisms within the PXR gene sequence are discussed as potential factors that could predispose individuals to developing breast cancer or altering disease course.

The authors note the translational implications of these insights: pharmacological modulation of PXR activity represents an opportunity to modify breast cancer initiation, progression, and metastasis. Figure 1 in the review outlines pharmacological tools available to examine PXR-mediated modification of breast cancer biology and suggests an important opportunity to advance therapeutic strategies targeting PXR. The review consolidates a range of mechanistic observations and clinical associations while emphasizing knowledge gaps. The authors conclude that further investigations are needed to clarify how PXR drives tumorigenesis in mammary tissue, to define the consequences of PXR polymorphisms in patient populations, and to assess the therapeutic potential of targeting PXR signaling in breast cancer.

Throughout, the review situates PXR as a multifunctional regulator connecting xenobiotic sensing and metabolism with cell-cycle control, apoptosis, inflammation, and drug resistance in breast cancer, and positions continued research into PXR biology as a promising avenue for understanding and potentially improving breast cancer outcomes.